Henry Sebesta – Founder, CEO

Henry Sebesta is a dynamic commercial leader with a proven track record of increasing revenue through new-market development, innovative lead and content generation, and fostering strategic corporate partnerships.

After obtaining a B.S. degree in Molecular, Cellular, and Development Biology from the University of Colorado Boulder, Henry worked for Smith & Nephew Orthopaedics as an endoscopic sports medicine representative, selling medical device capital and consumables to orthopedic surgeons at the University of Washington and nearby medical centers.

He went on to work as a product, marketing, and sales manager for a biotech startup called KromaTiD, which specializes in the implementation and analysis of custom single-cell molecular assays for cell and gene therapy developers. There, he is credited with co-inventorship and commercialization of KromaTiD’s directional Genomic Hybridization (dGH) in-Site platform, which has been used by pharmaceutical and therapy developers to detect viral vector integrants, copy numbers, and genomic DNA rearrangements within their cells for preclinical, IND-enabling studies.

After KromaTiD, he also served as the Director of Business Development for Tensentric, a design and engineering firm focused specifically on custom medtech and biopharma product development. Here, in addition to authoring technical product development proposals for top 5 pharmaceutical clients, he generated go-to-market strategies for custom cell and gene therapy service offerings, and introduced internal team systems for prospecting still in use by Tensentric today that increased new client introductions by over 1000% prior to his tenure.

These systems formed the basis for HSCC’s inception and service offerings. By combining only the most relevant, cost-effective lead sourcing with optimized custom outreach informed by real-world data, HSCC is leveraging nearly a decade of experience in health technologies and advanced therapeutics to bring clients real results.